News from ESMO 2016

News from the European Society for Medical Oncology Congress

Copenhagen, 7-11 October 2016

- “ESMO 2016 Press Release: Pembrolizumab New Option for First Line Treatment of Patients with Advanced Lung Cancer and High PD-L1 Expression” | 09 Oct 2016

“ESMO 2016 Press Release: Greater Patient Selection May be Needed for First Line Nivolumab to Improve Progression-free Survival in Advanced Lung Cance” | 09 Oct 2016

Comments are closed.